“Tobacco cessation provided a significant survival benefit for patients with lung cancer who quit smoking shortly before or after diagnosis, despite the severity of the disease. Results of this Roswell Park Cancer Institute–led study were published by Dobson Amato et al in the Journal of Thoracic Oncology.
“Roswell Park has a unique Tobacco Assessment and Cessation Service (TACS) that conducts a standardized tobacco use assessment for patients with lung cancer treated in the Thoracic Center and automatically refers patients who smoke to a dedicated tobacco cessation counseling service.
“Using data from TACS, 250 patients participated in the study. Those who had recently stopped smoking (50 patients) or quit after their first contact with TACS (71 patients) had reduced mortality rates compared with patients who continued to use tobacco. The median survival for patients who reported they had stopped smoking was 28 months, compared with 18 months for those who continued to use tobacco. The survival advantage for those who stopped smoking was adjusted for demographics, disease stage, and other health characteristics.”
“Lung cancer rates are dropping in young women in many regions of the globe, the only recent comprehensive analysis of lung cancer rates for women around the world finds. The study points to the success of tobacco control efforts around the world. Lung cancer is now the second leading cause of cancer death in women worldwide. An estimated 491,200 women died of lung cancer in 2012, more than half (57%) of whom resided in economically developing countries.”
IKBKE, a newly identified gene that is activated by tobacco, could be a fresh target for lung cancer therapies. A new study in the journal Oncogene sheds light on the molecular pathways surrounding the activation of IKBKE, which contributes to lung carcinogenesis.
Patients tend to develop resistance to traditional cancer treatments like chemotherapy and radiotherapy. However, the search for genetic therapy targets could yield individualized, powerful treatments that do not decrease in efficacy. Researchers at Florida’s Moffitt Cancer Center found that, in addition to playing a role in the development of chemoresistance, IKBKE is also part of a carcinogenic molecular pathway that can be set off by tobacco smoke. Continue reading…